0A5R

Calliditas Therapeutics Ab News

Best deals to access real time data!
Real-time Level 1 for London Stock Exchange
Monthly Subscription
for only
$29.56
London Stock Exchange Level 2
Monthly Subscription
for only
$77.61
Real-time London Stock Exchange & FTSE
Monthly Subscription
for only
$88.69
VAT not included
Company Name Stock Ticker Symbol Market Type
Calliditas Therapeutics Ab 0A5R London Ordinary Share
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% -
Open Price Low Price High Price Close Price Prev Close
more quote information »

Recent News

Date Time Source Heading
5/19/202210:46PRNUSBulletin from the annual general meeting of Calliditas..
5/19/202210:45PRNUSBulletin from the annual general meeting of Calliditas..
5/19/202208:44PRNUSCalliditas receives positive CHMP opinion in IgA nephropathy
5/19/202208:41PRNUSCalliditas receives positive CHMP opinion in IgA nephropathy
5/17/202205:18PRNUSFirst patient randomized in Phase 2 trial in head and neck..
5/17/202205:15PRNUSFirst patient randomized in Phase 2 trial in head and neck..
5/10/202202:44PRNUSCalliditas Therapeutics to participate in upcoming investor..
5/10/202202:43PRNUSCalliditas Therapeutics to participate in upcoming investor..
4/29/202204:18PRNUSNumber of shares and votes in Calliditas Therapeutics
4/29/202204:16PRNUSNumber of shares and votes in Calliditas Therapeutics
4/27/202212:13PRNUSCalliditas Therapeutics' 2021 Annual Report Published
4/27/202212:11PRNUSCalliditas Therapeutics' 2021 Annual Report Published
4/14/202203:30PRNUSNotice of annual general meeting of Calliditas Therapeutics..
4/14/202203:28PRNUSNotice of annual general meeting of Calliditas Therapeutics..
3/24/202207:11PRNUSCalliditas CEO acquires shares through the exercise of..
3/24/202207:10PRNUSCalliditas CEO acquires shares through the exercise of..
3/22/202203:24PRNUSCalliditas provides a regulatory update on EMA process for..
3/22/202203:20PRNUSCalliditas provides a regulatory update on EMA process for..
3/18/202203:19PRNUSUpdated regulatory plans for NEFECON in China
3/18/202203:18PRNUSUpdated regulatory plans for NEFECON in China
3/14/202202:24PRNUSExpansion of Everest Medicine's licence agreement to include..
3/14/202202:22PRNUSExpansion of Everest Medicine's licence agreement to include..
2/24/202204:41PRNUSYear-End Report, 2021
2/24/202201:37PRNUSYear-End Report, 2021
2/15/202204:40PRNUSFirst patient randomized in pivotal TRANSFORM study with..
2/15/202204:39PRNUSFirst patient randomized in pivotal TRANSFORM study with..
1/28/202202:16PRNUSCalliditas Therapeutics Announces Commercial Availability..
1/28/202202:14PRNUSCalliditas Therapeutics Announces Commercial Availability..
12/15/202117:05PRNUSFDA grants Calliditas Therapeutics Accelerated Approval of..
12/15/202117:04PRNUSFDA grants Calliditas Therapeutics Accelerated Approval of..
11/18/202101:21PRNUSCalliditas Therapeutics: Interim Report Q3, 2021
11/18/202101:12PRNUSCalliditas Therapeutics: Interim Report Q3, 2021
11/03/202104:42PRNUSCalliditas announces poster presentations at ASN Digital..
11/03/202104:40PRNUSCalliditas announces poster presentations at ASN Digital..
11/02/202105:17PRNUSCalliditas Therapeutics' nomination committee for the AGM..
10/07/202102:22PRNUSCalliditas announces acquisition of remaining Genkyotex..
10/07/202102:21PRNUSCalliditas announces acquisition of remaining Genkyotex..
9/16/202108:55PRNUSUpdated regulatory timeline for review of MAA in Europe
9/16/202108:52PRNUSUpdated regulatory timeline for review of MAA in Europe
9/14/202117:27PRNUSPDUFA goal date extension for Nefecon NDA in the U.S.
9/14/202117:26PRNUSPDUFA goal date extension for Nefecon NDA in the U.S.
8/31/202102:42PRNUSNumber of shares and votes in Calliditas Therapeutics
8/31/202102:40PRNUSNumber of shares and votes in Calliditas Therapeutics
8/19/202101:21PRNUSCalliditas Therapeutics: Interim Report Q2, 2021
8/19/202101:19PRNUSCalliditas Therapeutics: Interim Report Q2, 2021
8/12/202112:52PRNUSCalliditas Therapeutics intends to carry out a directed..
8/09/202103:15PRNUSCalliditas Receives FDA Fast Track Designation for setanaxib..
8/09/202103:14PRNUSCalliditas Receives FDA Fast Track Designation for setanaxib..
7/21/202103:05PRNUSCalliditas Therapeutics and STADA partner to register and..
7/15/202103:02PRNUSCalliditas secures $75 million term loan facility


Your Recent History
LSE
0A5R
Calliditas..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.